Evolent Health, Inc. (NYSE:EVH) Shares Bought by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. grew its holdings in Evolent Health, Inc. (NYSE:EVH - Free Report) by 53.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 350,155 shares of the technology company's stock after acquiring an additional 121,369 shares during the period. Salem Investment Counselors Inc. owned about 0.30% of Evolent Health worth $3,939,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Quarry LP purchased a new stake in shares of Evolent Health during the 2nd quarter worth $32,000. Covestor Ltd lifted its position in Evolent Health by 138.1% in the third quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock valued at $40,000 after acquiring an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its position in Evolent Health by 5,365.5% in the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock valued at $45,000 after acquiring an additional 1,556 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Evolent Health in the second quarter valued at about $61,000. Finally, Quest Partners LLC purchased a new stake in shares of Evolent Health in the second quarter valued at about $87,000.

Evolent Health Trading Down 1.4 %

NYSE:EVH traded down $0.17 during trading hours on Monday, reaching $12.37. 1,440,214 shares of the company were exchanged, compared to its average volume of 1,553,712. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -13.59 and a beta of 1.45. Evolent Health, Inc. has a 52-week low of $10.53 and a 52-week high of $35.00. The stock has a 50 day simple moving average of $12.69 and a 200 day simple moving average of $20.97.

Analyst Upgrades and Downgrades

EVH has been the topic of a number of recent analyst reports. Royal Bank of Canada reiterated an "outperform" rating and set a $20.00 price target on shares of Evolent Health in a research note on Tuesday, November 12th. JPMorgan Chase & Co. lowered their target price on shares of Evolent Health from $45.00 to $15.00 and set an "overweight" rating on the stock in a research report on Friday, November 22nd. Truist Financial lowered their target price on shares of Evolent Health from $24.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday. KeyCorp initiated coverage on shares of Evolent Health in a report on Friday, October 11th. They issued an "overweight" rating and a $35.00 price target on the stock. Finally, Barclays reduced their price target on shares of Evolent Health from $39.00 to $19.00 and set an "overweight" rating on the stock in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $22.83.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.